Genepharm Australasia

Genepharm Australasia was an Australian pharmaceutical company specializing in the development, registration, and distribution of generic prescription medicines. Based in Melbourne, the company focused on providing high-quality, cost-effective alternatives to branded pharmaceuticals across several key therapeutic areas, including cardiology, oncology, and the central nervous system. Genepharm Australasia was publicly listed on the Australian Securities Exchange under the ticker GAA. In 2012, the company was acquired by the United States-based Amneal Pharmaceuticals for approximately $26 million USD. This acquisition served as a strategic platform for Amneal to enter the Australian and Asia-Pacific markets, integrating Genepharm's extensive product portfolio and local expertise into its global operations.